Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious ...

BTIG analyst Julian Harrison has maintained their bullish stance on SYRE stock, giving a Buy rating on January 14.Invest with Confidence: ...

Fortune Brands recently announced it will consolidate its U.S offices into one headquarters, taking over two of three office buildings previously owned by Horizon Therapeutics, then Amgen Inc., at ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to deliver. Learn more on TGTX stock here.

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Eton Pharmaceuticals (ETON – Research Report), boosting the price ...

NDAQ:HOTH) Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications ...

In April 2023, Avacta Group dosed the first subject in the dose-escalation portion of its Phase I trial of AVA6000 in the US, ...

The Global Ophthalmic Disease Therapeutics market showcased growth ... healthcare infrastructure are anticipated to propel market expansion. The rising incidence of lifestyle-related eye diseases ...

The Pharmaceutical Technology Excellence Awards winners have been announced! Download our full 50+ page report to find out ...

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal ...